StreetInsider.com News Articles

Form S-8 AGIOS PHARMACEUTICALS,

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666268.html

Form S-8 AGIOS PHARMACEUTICALS,

Thu, 18 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260618/26666268.html

Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18

Thu, 18 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260618/26666153.html

Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18

Thu, 18 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260618/26666153.html

Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: Owen Adams Catherine

Tue, 16 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260616/26654177.html

Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: Owen Adams Catherine

Tue, 16 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260616/26654177.html

Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: CAPELLO JEFFREY D

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654115.html

Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: CAPELLO JEFFREY D

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654115.html

Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright

Mon, 15 Jun 2026 06:50:15 -0400

(Updated - June 15, 2026 6:50 AM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on Agios Pharma (NASDAQ: AGIO) to $54.00 (from $50.00) while maintaining a Buy rating.

The analyst commented: "Over the weekend, Agios presented numerous abstracts at EHA and hosted an investor webcast, highlighting new mitapivat data from RISE UP in SCD. We remind that the RISE UP Phase 3 trial (n=198; randomized 2:1 to mitapivat 100 mg BID or placebo) met the primary endpoint of Hb response, but did not meet the primary endpoint of annualized rate of sickle cell pain crises (SCPC) over the 52-week

Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright

Mon, 15 Jun 2026 06:50:15 -0400

(Updated - June 15, 2026 6:50 AM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on Agios Pharma (NASDAQ: AGIO) to $54.00 (from $50.00) while maintaining a Buy rating.

Agios presents Phase 3 sickle cell disease trial results at EHA conference

Sat, 13 Jun 2026 09:00:15 -0400

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) presented detailed results from its RISE UP Phase 3 trial of mitapivat for sickle cell disease at the European Hematology Association Congress in Stockholm. The 52-week study evaluated the oral pyruvate kinase activator in 207 patients aged 16 years or older.

The trial met its primary endpoint, with 40.6% of patients receiving mitapivat achieving hemoglobin response compared to 2.9% on placebo. Hemoglobin response was defined as a 1.0 g/dL or greater increase from baseline in average hemoglobin levels from Week 24 through Week 52.

New analyses showed patients receiving mitapivat had a 41.1% relative reduction in the

Agios presents Phase 3 sickle cell disease trial results at EHA conference

Sat, 13 Jun 2026 09:00:15 -0400

New analyses showed patients receiving mitapivat had a 41.1% relative reduction in the

Agios presents Phase 3 sickle cell disease trial results at EHA conference

Sat, 13 Jun 2026 09:00:15 -0400

New analyses showed patients receiving mitapivat had a 41.1% relative reduction in the

Agios presents Phase 3 sickle cell disease trial results at EHA conference

Sat, 13 Jun 2026 09:00:15 -0400

New analyses showed patients receiving mitapivat had a 41.1% relative reduction in the

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease